About Ambagon
Ambagon is a Healthcare company based in San Francisco (United States) founded in 2020 by Luc Brunsveld, Christian Ottmann, and Michelle Arkin. Small-molecule therapeutics for cancer treatment are developed. Ambagon has raised $108 million across 3 funding rounds from investors including AbbVie, Citadel and RA Capital. Its chief executive, as recorded, is Scott Clarke. Ambagon offers products and services including Molecular Glue Platform. Its focus areas include Life Sciences, Oncology, Drugs and Breast Cancer. Its competitors include Daré Bioscience, Olema Oncology and Atossa Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Ambagon was founded in 2020 and is headquartered in San Francisco, United States. Small-molecule therapeutics targeting cancer are developed within the biotechnology sector. Focus is placed on drugs that stabilize interactions between oncogenic proteins and the 14-3-3 class of adaptor proteins. A novel method is employed to inhibit oncogenic transcription factors in cancers driven by specific genetic alterations. Operations center on advancing these therapeutics through research and development.
- Headquarters San Francisco, United States
- Founders Luc Brunsveld, Christian Ottmann, Michelle Arkin
- SectorsHealthcare
- Email••••••••
- Website ambagontx.com
- Social LinkedIn X
- Total Equity Funding$108M (USD)
in 3 rounds
- Latest Funding Round$5M (USD), Series A
Jan 2025
- InvestorsAbbVie
& 7 more
Products & Services of Ambagon
Ambagon offers a comprehensive portfolio of products and services, including Molecular Glue Platform.
Platform for developing medicines targeting undruggable proteins.
Funding Insights of Ambagon
Ambagon has successfully raised a total of $108M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $108M
- Total Rounds 3
- Last Round Series A — $5M
- First Round $18M
(Nov 2021)
- Investors Count 8
All 3 funding rounds of Ambagon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $5M | Series A | – | – | – |
| Jan 2022 | $85M | Series A | – | Nextech Invest | |
| Nov 2021 | $18M | Seed | – | RA Capital Management, Inkef Capital | – |
8 investors in total: 8 institutional.
Investors in Ambagon
Ambagon has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, Citadel and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Early & late stage VC firm investing primarily in Netherlands | inkefcapital.com | Amsterdam, Netherlands | ||
Investments in life science startups are made by Mission BioCapital. | missionbiocapital.com | San Francisco, United States | ||
Seed and early-stage therapeutics companies are invested in by MRLV. | mrlv.com | Cambridge, United States | ||
Droia Ventures is focused on investing in drug development companies. | droia.be | Luxembourg, Luxembourg | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States |
Investor details for Ambagon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ambagon
23 people are tracked at Ambagon (7 in leadership, 8 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Luc Brunsveld | Co-Founder | Leadership |
Christian Ottmann | Co-Founder | Leadership |
Michelle Arkin | Co-Founder | Leadership |
Scott Clarke | CEO | Leadership |
Tanja Meyer | VP & Head, Corporate Strategy & Business Development | Leadership |
Jinxia Nancy Deng | Senior Director, Computational Chemistry | Leadership |
Maarten Altelaar | Executive Director | Leadership |
Carolyn Bertozzi | Scientific Advisor | Board & advisors |
Alan Ashworth | Scientific Advisor | Board & advisors |
Steve Davidsen | Scientific Advisor | Board & advisors |
Geraldine Harriman | Scientific Advisor | Board & advisors |
Ali Tavassoli | Scientific Advisor | Board & advisors |
Peter Dudek | Director | Board & advisors |
Janwillem Naesens | Director | Board & advisors |
Margarita Chavez | Director | Board & advisors |
Laura Demmers | Senior Scientist | Team |
Loes Stevers | Principal Scientist Biochemistry | Team |
Donna Olivia Debets | Senior Scientist Proteomics | Team |
Taggra Jackson | Sr. Research Associate | Team |
Neil Richardson | Contract Manager | Team |
3 more people are available in the full profile.
Complete people profiles for Ambagon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ambagon
3 dated milestones of Ambagon across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Ambagon is founded.
- Funding First funding round of $18.0M.
- Funding Latest funding round, Series A, of $5.0M.
Competitors of Ambagon
Ambagon has 3 listed competitors in our database, 2 of them funded. They include Daré Bioscience, Olema Oncology and Atossa Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| darebioscience.com | 2005 | San Diego, United States | 30 | Non-hormonal pharmaceutical products for female contraceptives are developed. | ||
| olema.com | 2007 | San Francisco, United States | $139M | 74 | Drug therapeutics for breast cancer treatment are developed. | |
| atossatherapeutics.com | 2009 | Seattle, United States | $13.52M | 10 | Drugs for breast cancer treatment and prevention are developed. |
Detailed competitors of Ambagon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Ambagon (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ambagon
Complete news archive for Ambagon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ambagon
Ambagon was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Ambagon is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Scott Clarke is the CEO of Ambagon, as recorded in our data.
Ambagon is a funded company, having raised a total of $108M across 3 funding rounds to date. The company's 1st funding round was a Seed of $18M, raised on Nov 2021.
Ambagon was founded in 2020 and is headquartered in San Francisco, United States. Small-molecule therapeutics targeting cancer are developed within the biotechnology sector. Focus is placed on drugs that stabilize interactions between oncogenic proteins and the 14-3-3 class of adaptor proteins. A novel method is employed to inhibit oncogenic transcription factors in cancers driven by specific genetic alterations. Operations center on advancing these therapeutics through research and development.
Ambagon's top competitors include Atossa Therapeutics, Daré Bioscience and Olema Oncology.
Ambagon offers Molecular Glue Platform.
Ambagon has 8 investors. Key investors include AbbVie, Citadel, RA Capital, Nextech Invest, and Inkef Capital.